GeneDx Holdings Corp. Class A Common Stock (WGS) is a publicly traded Healthcare sector company. As of May 21, 2026, WGS trades at $44.09 with a market cap of $1.27B and a P/E ratio of -59.93. WGS moved +6.22% today. Year to date, WGS is -65.98%; over the trailing twelve months it is -37.97%. Its 52-week range spans $32.21 to $170.87. Analyst consensus is strong buy with an average price target of $91.25. Rallies surfaces WGS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
GeneDx Cuts 2026 Revenue Outlook to $475–490M After 34% Volume Surge: GeneDx delivered 34% year-over-year exome and genome test volume growth to 27,488 tests and 17% revenue growth to $102.3 million in Q1 2026, alongside an $8.2 million adjusted net loss. The company reduced full-year revenue guidance to $475–490 million and projects at least 30% volume growth.
| Metric | Value |
|---|---|
| Price | $44.09 |
| Market Cap | $1.27B |
| P/E Ratio | -59.93 |
| EPS | $-0.73 |
| Dividend Yield | 0.00% |
| 52-Week High | $170.87 |
| 52-Week Low | $32.21 |
| Volume | 999.66K |
| Avg Volume | 0 |
| Revenue (TTM) | $427.54M |
| Net Income | $-21.02M |
| Gross Margin | 69.74% |
8 analysts cover WGS: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $91.25.